Trial Profile
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Ustekinumab in Subjects With Primary Biliary Cirrhosis Who Had an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Primary biliary cirrhosis
- Focus Proof of concept; Therapeutic Use
- Acronyms PURIFI
- Sponsors Janssen Research & Development; Janssen-Cilag
- 24 Nov 2015 Results published in the Hepatology
- 29 Oct 2014 New trial record